Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
26 hedge funds and large institutions have $421M invested in Sinovac Biotech, Ltd in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
225% more funds holding
Funds holding: 8 → 26 (+18)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
23% more capital invested
Capital invested by funds: $342M → $421M (+$78.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$76.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.04M |
| 3 |
Renaissance Technologies
New York
|
+$849K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$179K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$106K |
Top Sellers
SVA Hedge Fund Activity: Q1 2024 in Review
26 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2024, worth a combined $421M — up 23% from $342M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SVA positions and 0 closed out — a net gain of 18 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $76.3M.
- 26 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2024, up from 8 in Q4 2023.
- Funds reported $421M of Sinovac Biotech, Ltd stock for Q1 2024, up 23% quarter-over-quarter.
- 18 funds opened new Sinovac Biotech, Ltd positions in Q1 2024 and 0 closed out, a net change of +18 holders.
- The largest Sinovac Biotech, Ltd buyer in Q1 2024 was Vivo Capital, an estimated $76.3M added.
Based on aggregated 13F filings for Q1 2024.